CLINICAL TRIALS PROFILE FOR JNJ-56136379
✉ Email this page to a colleague
Clinical Trials for JNJ-56136379
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02662712 ↗ | A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chro | Completed | Janssen Sciences Ireland UC | Phase 1 | The purpose of this study is to evaluate pharmacokinetics and safety data including serious and other adverse events, physical examinations, vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory results (including biochemistry, hematology, and urine). |
| NCT02933580 ↗ | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants | Completed | Janssen Research & Development, LLC | Phase 1 | The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions. |
| NCT03111511 ↗ | A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Prob | Completed | Janssen Sciences Ireland UC | Phase 1 | The main purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-56136379 on the single-dose pharmacokinetics (PK) of drospirenone and ethinylestradiol (oral contraceptive [OC]) in healthy female participants and to evaluate the effect of steady-state concentrations of JNJ-56136379 on the single-dose PK of midazolam (sensitive probe substrate for CYP3A4) in healthy female participants. |
| NCT03361956 ↗ | An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection | Completed | Janssen Sciences Ireland UC | Phase 2 | The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels. |
| NCT03864601 ↗ | A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants | Completed | Janssen Research & Development, LLC | Phase 1 | The purpose of this study is to investigate the absorption, the metabolic pathways, the route and rate of elimination, and total recovery of 14C-JNJ-56136379 and/or total drug derived radioactivity in healthy male adult participants after administration of a single oral dose of 14C-JNJ-56136379. |
| NCT03945539 ↗ | A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants | Completed | Janssen Sciences Ireland UC | Phase 1 | The main purpose of this study is to assess the effect of itraconazole at steady-state on a single-dose pharmacokinetic (PK) of JNJ-56136379 in healthy adult participants. |
| NCT03982186 ↗ | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection | Active, not recruiting | Janssen Sciences Ireland UC | Phase 2 | The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for JNJ-56136379
Condition Name
Clinical Trial Locations for JNJ-56136379
Trials by Country
Clinical Trial Progress for JNJ-56136379
Clinical Trial Phase
Clinical Trial Sponsors for JNJ-56136379
Sponsor Name
